ArticleMolecular and clinical oncology2026
D-dimer as a more effective marker for detecting thrombosis in patients with ovarian clear cell carcinoma compared with high-grade serous carcinoma.
Article in Molecular and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present retrospective cohort study aimed to examine the effectiveness of D-dimer in detecting cancer-associated thromboembolism (CAT) in clear cell carcinoma (CCC) compared with that in high-grade serous carcinoma (HGSC) to develop an effective screening method. Patients diagnosed with CCC or HGSC who underwent primary surgery at National Defense Medical College Hospital (Tokorozawa, Japan) between January 2009 and December 2023 were included in the present study, and their clinical records were analyzed. Patients with a history of thrombosis and anticoagulation and those with acute infection at the initial visit were excluded. In the CCC and HGSC groups, 20 out of 79 patients (25.3%) and 15 out of 123 patients (12.2%) developed CAT, respectively, indicating that CAT was more common in patients with CCC (P=0.022). D-dimer was a significantly better predictor in CCC [area under the curve (AUC), 0.92] than in HGSC (AUC, 0.75). Multivariate analysis demonstrated that the International Federation of Gynecology and Obstetrics (FIGO) stage was an independent risk factor for CAT (odds ratio, 3.28; 95% CI, 1.04-10.3; P=0.042) in the CCC group. For CAT detection, combining D-dimer with FIGO stage further improved the predictive accuracy in early-stage CCC (AUC, 0.97). These results may be useful for CAT screening in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.